NCT07502664 Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
| NCT ID | NCT07502664 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ray Therapeutics, Inc. |
| Condition | Retinitis Pigmentosa |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-02-19 |
| Primary Completion | 2027-02 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records * Best-corrected visual acuity between 20/200 to HM in at least one eye. * Reasonably fluent in English or Spanish Exclusion Criteria: * Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing. * Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol * Current pregnancy as reported by patient